Skip to main content
OpenTrials
Completed

NCT Number: NCT02216461

Safety, Tolerability and Pharmacokinetics of BIBW 2948 BS for HandiHaler® in Healthy Male Volunteers

To investigate safety, tolerability, and pharmacokinetics of BIBW 2948 BS after repeated dosing

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

21 year–50 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy males based on a complete medical history, including the physical examination, vital signs (BP, PR), 12-lead ECG, clinical laboratory tests
  • Age ≥21 and Age ≤ 50 years
  • BMI (Body Mass Index) ≥18.5 and BMI ≤ 29.9 kg/m2
  • Signed and dated written informed consent prior to admission to the study in accordance with good clinical practice (GCP) and the local legislation
  • Subjects must be current smokers (<10 cigarettes or <3 cigars <3 pipes/day) with a smoking history >1 year

Exclusion criteria

  • Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance
  • Any evidence of a clinically relevant concomitant disease
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • History of relevant orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of relevant allergy/hypersensitivity (including allergy to the drug or its excipients)
  • Intake of drugs with a long half-life (>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
  • Use of drugs which may have reasonably influenced the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
  • Participation in another trial with an investigational drug within two months prior to administration or during the trial
  • Smoker (>10 cigarettes or >3 cigars or >3 pipes/day)
  • Inability to refrain from smoking on trial days
  • Alcohol abuse (more than 60 g/day)
  • Drug abuse
  • Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
  • Excessive physical activities (within one week prior to administration or during the trial)
  • Any laboratory value outside the reference range that is of clinical relevance
  • Inability to comply with dietary regimen of study centre

Treatment and study plan

Low dose of BIBW 2948 BS for oral inhalation

Drug

Medium dose of BIBW 2948 BS for oral inhalation

Drug

High dose of BIBW 2948 BS for oral inhalation

Drug

Placebo

Drug

Primary outcomes

  1. Number of patients with clinically significant findings in vital signs

    Time frame: Up to day 20 after start of treatment

  2. Number of patients with clinically significant findings in 12-lead electrocardiogram (ECG)

    Time frame: Up to day 20 after start of treatment

  3. Number of patients with clinically significant findings in clinical laboratory tests

    Time frame: Up to day 20 after start of treatment

  4. Number of patients with adverse events

    Time frame: Up to day 41

  5. Assessment of tolerability by investigator on a 4-point scale

    Time frame: Up to day 20 after start of treatment

Secondary outcomes

  1. Maximum concentration of the analyte BIBW in plasma at different time points (Cmax)

    Time frame: Pre-dose, up to 336 hours after start of treatment

  2. Time from dosing to maximum measured concentration of the analyte in plasma at different time points (tmax)

    Time frame: Pre-dose, up to 336 hours after start of treatment

  3. area under the concentration-time curve of the analyte in plasma over a uniform dosing interval τ (AUCτ,1)

    Time frame: Pre-dose, up to 336 hours after start of treatment

  4. The percentage of the area under the concentration-time curve of the analyte in plasma over the time interval from 0 to infinity (AUC0-∞) that is obtained by extrapolation (%AUCtz-∞)

    Time frame: Pre-dose, up to 336 hours after start of treatment

  5. Terminal rate constant of the analyte in plasma at different time points (λz)

    Time frame: Pre-dose, up to 336 hours after start of treatment

  6. Terminal half-life of the analyte in plasma at different time points (t1/2)

    Time frame: Pre-dose, up to 336 hours after start of treatment

  7. Mean residence time of the analyte in the body after one administration at different time points (MRTih)

    Time frame: Pre-dose, up to 336 hours after start of treatment

  8. Apparent clearance of the analyte in plasma following extravascular administration at different time points (CL/F)

    Time frame: Pre-dose, up to 336 hours after start of treatment

  9. Apparent volume of distribution during the terminal phase λz following an extravascular administration at different time points (Vz/F)

    Time frame: Pre-dose, up to 336 hours after start of treatment

  10. Amount of analyte that is eliminated in urine from at different time points (Ae)

    Time frame: Pre-dose, up to 336 hours after start of treatment

  11. Fraction of analyte eliminated in urine at different time points (fe)

    Time frame: Pre-dose, up to 336 hours after start of treatment

  12. Renal clearance of the analyte at different time points (CLR)

    Time frame: Pre-dose, up to 336 hours after start of treatment

  13. Minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmin,ss)

    Time frame: Pre-dose, up to 336 hours after start of treatment

  14. Accumulation ratio of the analyte in plasma after multiple dose administration over a uniform dosing interval τ based on Cmax (RA,Cmax,10)

    Time frame: Pre-dose, up to 336 hours after start of treatment

  15. Accumulation ratio of the analyte in plasma after multiple dose administration over a uniform dosing interval τ based on AUC0-τ (RA,AUC,10)

    Time frame: Pre-dose, up to 336 hours after start of treatment

  16. Linearity index (AUCτ,ss / AUC0-∞)

    Time frame: Pre-dose, up to 336 hours after start of treatment

  17. Changes from baseline in induced sputum analysis (amount of cells, mucin)

    Time frame: Pre-dose, 268 hours after start of treatment

  18. area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)

    Time frame: Pre-dose, up to 336 hours after start of treatment

  19. area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable concentration at tz (AUC0-tz)

    Time frame: Pre-dose, up to 336 hours after start of treatment

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

Safety, Tolerability and Pharmacokinetics of Multiple Rising Inhaled Doses (7.5 to 60 mg Daily for 12 Days) of BIBW 2948 BS Inhalation Powder, Hard Capsule for HandiHaler® in Healthy Male Volunteers (Randomised, Double-blind Placebo-controlled Within Dose Groups)

Important dates

Study start
2006
Primary completion
2006
First posted
Aug 15, 2014
Registry last updated
Aug 15, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.